US FDA’s Post-Aduhelm Reforms Include Updated Alzheimer’s Development Guidance, Record-Keeping On Sponsor Meetings
• By M. Nielsen Hobbs
FDA will continue to have to navigate the treacherous seas of the Aduhelm controversy in 2023. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
